KEYNOTE-177: 5-Year Update with Dr. Kai-Keen Shiu

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 04:53

Dr. Kai-Keen Shiu, Consultant Medical Oncologist at the UCL Cancer Institute and lead investigator in the KEYNOTE-177 trial, summarises data from the 5-year follow-up of the Phase III trial for patients with advanced MSI-H/dMMR mCRC.1

dMMR = Mismatch Repair-Deficient; mCRC = Metastatic Colorectal Cancer; MSI-H = Microsatellite Instability-High

More information about KEYTRUDA® (pembrolizumab) in metastatic CRC


  1. Shiu KK, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study. ESMO. 20–24 October 2023. Madrid, Spain.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website